---
title: "Beam Therapeutics Q2 FY26 net loss widens to $122.7 million; revenue drops to $490,000"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294811887.md"
description: "Beam Therapeutics reported a widened Q2 FY26 net loss of $122.7 million, with revenue dropping to $490,000 from $8.47 million previously. R&D expenses decreased to $95.1 million, while G&A rose to $31.9 million. The company holds $1.2 billion in cash, projecting a runway into mid-2029. Clinically, the first patient was dosed in the BEAM-302 pivotal cohort, and risto-cel Phase 1/2 dosing is complete, with a BLA submission expected by late 2026."
datetime: "2026-08-04T11:06:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294811887.md)
  - [en](https://longbridge.com/en/news/294811887.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294811887.md)
generator: "portal-rs"
---

# Beam Therapeutics Q2 FY26 net loss widens to $122.7 million; revenue drops to $490,000

-   Beam Therapeutics posted a wider Q2 2026 net loss of USD 122.7 million, or USD 1.18 per share. \* Revenue fell to USD 490,000 from USD 8.47 million a year earlier. \* R&D spending dipped to USD 95.1 million, while G&A climbed to USD 31.9 million. \* Cash, cash equivalents, and marketable securities totaled USD 1.2 billion; cash runway expected into mid-2029, including a planned USD 200 million draw. \* First patient dosed in BEAM-302 global pivotal cohort; risto-cel dosing completed in Phase 1⁄2 BEACON, with BLA submission expected as early as year-end 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608040700PRIMZONEFULLFEED9802653) on August 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [BEAM.US](https://longbridge.com/en/quote/BEAM.US.md)

## Related News & Research

- [Beam Therapeutics Inc. 2Q 2026: Revenue $0.5M, EPS $(1.18) — 10-Q Summary](https://longbridge.com/en/news/294814748.md)
- [Xcel Energy sets BRL 0.26 per unit distribution for payment Oct. 26, 2026](https://longbridge.com/en/news/296646864.md)
- [Itera ASA to present preliminary Q2 2026 results via webcast](https://longbridge.com/en/news/296590225.md)
- [Public Storage announces R$ 0.41 per unit dividend for Q3 2026](https://longbridge.com/en/news/296635332.md)
- [Corning sets Q3 2026 dividend at R$ 0.25 per unit](https://longbridge.com/en/news/296635714.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**